Aims
Capmatinib, an orally bioavailable, highly potent and selective MET
inhibitor, was recently approved to treat adult patients with metastatic
non-small cell lung cancer with METex14 skipping mutations. The
study investigated the effect of capmatinib on the pharmacokinetics of a
single oral dose of digoxin and rosuvastatin, administered orally as a
two-drug cocktail in patients with MET -dysregulated advanced
solid tumors.